Related references
Note: Only part of the references are listed.Downregulation of BCL2 by miRNAs augments drug-induced apoptosis - a combined computational and experimental approach
Richa Singh et al.
JOURNAL OF CELL SCIENCE (2012)
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells
Belal Azab et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
James L. LaBelle et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
James W. Hodge et al.
SEMINARS IN ONCOLOGY (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
Hanshi Sun et al.
BLOOD (2011)
Targeting Mcl-1 for the therapy of cancer
Bridget A. Quinn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
The BH3 α-Helical Mimic BH3-M6 Disrupts Bcl-XL, Bcl-2, and MCL-1 Protein-Protein Interactions with Bax, Bak, Bad, or Bim and Induces Apoptosis in a Bax- and Bim-dependent Manner
Aslamuzzaman Kazi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity
Rupesh Dash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
An optically pure apogossypolone derivative as potent pan -active inhibitor of anti-apoptotic BcI-2 family proteins
Jun Wei et al.
FRONTIERS IN ONCOLOGY (2011)
Mitochondrial signaling in cell death via the Bcl-2 family
Brian Leibowitz et al.
CANCER BIOLOGY & THERAPY (2010)
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Scott Ackler et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells
Jingxuan Pan et al.
CANCER LETTERS (2010)
A Bax-Mediated Mechanism for Obatoclax-Induced Apoptosis of Cholangiocarcinoma Cells
Rory L. Smoot et al.
CANCER RESEARCH (2010)
Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
Jimmy J. Hwang et al.
CLINICAL CANCER RESEARCH (2010)
Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia
Claudia Bincolettu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine
Benedetto Farsaci et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Synthesis and Biological Evaluation of Apogossypolone Derivatives as Pan-active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
Jun Wei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
Jun Wei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Stephen K. Tahir et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Martin Schwickart et al.
NATURE (2010)
GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
N. Heidari et al.
CELL DEATH & DISEASE (2010)
Molecular fingerprinting of radiation resistant tumors: Can we apprehend and rehabilitate the suspects?
Charles J. Rosser et al.
BMC CANCER (2009)
Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma
William A. Michaud et al.
CLINICAL CANCER RESEARCH (2009)
Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands
Erinna F. Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway
Zhe-Yu Hu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins
Jun Wei et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi et al.
BLOOD (2008)
A short Nur77-derived peptide converts Bcl-2 from a protector to a killer
Siva Kumar Kolluri et al.
CANCER CELL (2008)
sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell
Defeng Tian et al.
CANCER LETTERS (2008)
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)
Marina Konopleva et al.
CANCER RESEARCH (2008)
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
Christine L. Hann et al.
CANCER RESEARCH (2008)
被撤回的出版物: TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer(Retracted article. See vol.139,pg.2146,2016)
Zhiwei Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
Cheol-Min Park et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Mimicking the BH3 domain to kill cancer cells
T. Ni Chonghaile et al.
ONCOGENE (2008)
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
Mai Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Surface plasmon resonance in nanocrystalline gold-copper alloy films
S. Hussain et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2007)
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress
Mohamed Rahmani et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1
M. Chiara Maiuri et al.
EMBO JOURNAL (2007)
Crystal structure of the Bcl-XL-beclin 1 peptide complex -: Beclin 1 is a novel BH3-only protein
Adam Oberstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1
Ramzi M. Mohammad et al.
CLINICAL CANCER RESEARCH (2007)
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak
Simon N. Willis et al.
SCIENCE (2007)
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel et al.
CLINICAL CANCER RESEARCH (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins
Guoping Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak
Carolina Castilla et al.
ENDOCRINOLOGY (2006)
Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2
Benjamin D. Zeitlin et al.
CANCER RESEARCH (2006)
Cell death in the absence of Bax and Bak
T. Lindsten et al.
CELL DEATH AND DIFFERENTIATION (2006)
The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death
F Manero et al.
CANCER RESEARCH (2006)
Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy
W Sieghart et al.
JOURNAL OF HEPATOLOGY (2006)
Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry
GW Dai et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
miR-15 and miR-16 induce apoptosis by targeting BCL2
A Cimmino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis
Q Zhong et al.
CELL (2005)
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis
A Nencioni et al.
BLOOD (2005)
Discovery, characterization, and structure - Activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins
S Kitada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Integral role of Noxa in p53-mediated apoptotic response
T Shibue et al.
GENES & DEVELOPMENT (2003)
Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression
S Pelengaris et al.
CELL (2002)
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas
K Shigemasa et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Bcl-xL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy
E Heere-Ress et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy
K Stahnke et al.
BLOOD (2001)
Cellular stress response and apoptosis in cancer therapy
I Herr et al.
BLOOD (2001)
The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway
LH Wei et al.
ONCOGENE (2001)
Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis
CM Eischen et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
PUMA, a novel proapoptotic gene, is induced by p53
K Nakano et al.
MOLECULAR CELL (2001)
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
SP Tzung et al.
NATURE CELL BIOLOGY (2001)
Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential
RA Olie et al.
DRUG RESISTANCE UPDATES (2001)
Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
E Oda et al.
SCIENCE (2000)
A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax
S Kagawa et al.
GENE THERAPY (2000)
Share Paper
